bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2020-65-4-514-526bloodjour-244Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCASE REPORTSАнемия при первичном гиперпаратиреозеAnemia in primary hyperparathyroidismhttps://orcid.org/0000-0003-2669-9457ГорбачеваА. М.GorbachevaA. M.

Горбачева Анна Максимовна, врач-эндокринолог, научный сотрудник отделения патологии околощитовидных желез

117036, Москва

Annа M. Gorbacheva, Endocrinologist, Researcher, Department of Parathyroid Disorders

117036, Moscow

gorbacheva.anna@endocrincentr.ruhttps://orcid.org/0000-0002-9215-4984ШкляевС. С.ShklyayevS. S.

Шкляев Станислав Сергеевич, кандидат медицинских наук, гематолог, трансфузиолог

117036, Москва125284, Москва

Stanislav S. Shklyayev, Cand. Sci. (Med.), Physician (haematology and transfusiology)

117036, Moscow125284, Moscow 

staniss1@yahoo.comhttps://orcid.org/0000-0001-6667-062XEремкинаА. К.EremkinaA. K.

Eремкина Анна Константиновна, кандидат медицинских наук, врач-эндокринолог, заведующая отделением патологии околощитовидных желез

117036, Москва

Annа K. Eremkina, Cand. Sci. (Med.), Endocrinologist, Head of the Department of Parathyroid Disorders

117036, Moscow

eremkina.anna@endocrincentr.ruhttps://orcid.org/0000-0002-7867-4836БратчиковаА. А.BratchikovaA. A.

Братчикова Алина Андреевна, клинический ординатор

117036, Москва

Alina A. Bratchikova, Clinical Resident

117036, Moscow

bratchikovaalina@yandex.ruhttps://orcid.org/0000-0002-9717-9742МокрышеваН. Г.MokryshevaN. G.

Мокрышева Наталья Георгиевна, доктор медицинских наук, член-корреспондент РАН; директор

117036, Москва

Natalya G. Mokrysheva, Dr. Sci. (Med.), Corresponding Member of Russian Academy of Sciences, Director

117036, Moscow

parathyroid.enc@gmail.comФГБУ «Национальный медицинский исследовательский центр эндокринологии» Министерства здравоохранения Российской ФедерацииРоссияNational Research Center for EndocrinologyRussian FederationФГБУ «Национальный медицинский исследовательский центр эндокринологии» Министерства здравоохранения Российской Федерации; Медицинский радиологический научный центр им. А. Ф. Цыба — филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской ФедерацииРоссияNational Research Center for Endocrinology; A. Tsyb Medical Radiological Research Center — Branch of the National Medical Research Radiological CenterRussian Federation202009122020654514526Copyright © Горбачева А.М., Шкляев С.С., Eремкина А.К., Братчикова А.А., Мокрышева Н.Г., 20202020Горбачева А.М., Шкляев С.С., Eремкина А.К., Братчикова А.А., Мокрышева Н.Г.Gorbacheva A.M., Shklyayev S.S., Eremkina A.K., Bratchikova A.A., Mokrysheva N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/244Введение

Введение. Одним из осложнений первичного гиперпаратиреоза (ПГПТ) является анемия. В патогенезе ПГПТ-ассоциированной анемии принимают участие как ассоциированное с основным заболеванием ингибирование пролиферации клеток эритроидного ростка, так и неспецифические факторы (кровопотеря, хроническая болезнь почек), однако однозначного понимания патогенетических механизмов развития такого рода анемии нет.

Цель — представить клиническое наблюдение больной ПГПТ со сложным многокомпонентным генезом анемии.

Основные сведения

Основные сведения. Имеются указания на возможные взаимосвязи между ПГПТ и анемиями, однако отсутствуют большие клинические исследования, на основании которых могли бы быть сформированы алгоритмы ведения больных. Генез анемии в представленном клиническом случае имел многофакторный характер, не позволяющий исключить ПГПТ как одну из этиологических причин.

Introduction

Introduction. Anaemia is a complication of primary hyperparathyroidism (PHPT). Pathogenesis of PHPT-induced anaemia involves inhibited erythroid cell proliferation associated with the underlying disease and non-specific factors (blood loss, chronic kidney disease). However, its specific mechanisms remain unclear.

Aim

Aim. Clinical description of a PHPT case with multifactorial complicating anaemia.

Main findings

Main findings. With putative evidence existing on relationships between PHPT and anaemia, no large clinical trials substantiated suitable algorithms for such patients’ management. The genesis of anaemia reported in this case was multifactorial and not decisively excluding PHPT from putative causes.

анемияпервичный гиперпаратиреозanaemiaprimary hyperparathyroidismReferencesYeh M.W., Ituarte P.H.G., Zhou H.C. et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013; 98(3): 1122–9. DOI: 10.1210/jc.2012-4022.Yeh M.W., Ituarte P.H.G., Zhou H.C. et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013; 98(3): 1122–9. DOI: 10.1210/jc.2012-4022.Adami S., Marcocci C., Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 2002; 17(Suppl 2): N18–23.Adami S., Marcocci C., Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 2002; 17(Suppl 2): N18–23.Yu N., Donnan P.T., Murphy M.J. et al. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol. 2009; 71(4): 485–93. DOI: 10.1111/j.1365-2265.2008.03520.x.Yu N., Donnan P.T., Murphy M.J. et al. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol. 2009; 71(4): 485–93. DOI: 10.1111/j.1365-2265.2008.03520.x.Wermers R.A., Khosla S., Atkinson E.J. et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006; 21(1): 171–7. DOI: 10.1359/JBMR.050910.Wermers R.A., Khosla S., Atkinson E.J. et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006; 21(1): 171–7. DOI: 10.1359/JBMR.050910.Мокрышева Н.Г., Мирная С.С., Добрева Е.А. и др. Первичный гиперпаратиреоз в России по данным Регистра. Проблемы эндокринологии. 2019; 65(5): 300–10. DOI: 10.14341/probl10126.Mokrysheva N.G., Mirnaya S.S., Dobreva E.A. et al. Primary hyperparathyroidism in Russia according to the registry. Problemy endokrinologii. 2019; 65(5): 300–10. DOI: 10.14341/probl10126 (In Russian).Hunter D. Hyperparathyroidism: Generalized osteitis fibrosa with multiple osteoclastomata. Proc R Soc Med. 1931; 24(4): 486–96.Hunter D. Hyperparathyroidism: Generalized osteitis fibrosa with multiple osteoclastomata. Proc R Soc Med. 1931; 24(4): 486–96.Aub J.C., Albright F., Bauer W. et al. Studies of calcium and phosphorus metabolism: VI. In hypoparathyroidism and chronic steatorrhea with tetany with special consideration of the therapeutic effect of thyroid. J Clin Invest. 1932; 11(1): 211–34. DOI: 10.1172/JCI100404.Aub J.C., Albright F., Bauer W. et al. Studies of calcium and phosphorus metabolism: VI. In hypoparathyroidism and chronic steatorrhea with tetany with special consideration of the therapeutic effect of thyroid. J Clin Invest. 1932; 11(1): 211–34. DOI: 10.1172/JCI100404.Bernheim J., Rathaus V., Rathaus M. et al. Anemia in primary hyperparathyroidism. Nephrologie. 1986; 7(1): 28–30.Bernheim J., Rathaus V., Rathaus M. et al. Anemia in primary hyperparathyroidism. Nephrologie. 1986; 7(1): 28–30.Mallette L.E. Hyporegenerative anemia in primary hyperparathyroidism. South Med J. 1977; 70(10): 1199–201. DOI: 10.1097/00007611-19771000000014.Mallette L.E. Hyporegenerative anemia in primary hyperparathyroidism. South Med J. 1977; 70(10): 1199–201. DOI: 10.1097/00007611-19771000000014.Mallette L.E., Bilezikian J.P., Heath D.A. et al. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore). 1974; 53(2): 127–46.Mallette L.E., Bilezikian J.P., Heath D.A. et al. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore). 1974; 53(2): 127–46.Boxer M., Ellman L., Geller R. et al. Anemia in primary hyperparathyroidism. Arch Intern Med. 1977; 137(5): 588–93.Boxer M., Ellman L., Geller R. et al. Anemia in primary hyperparathyroidism. Arch Intern Med. 1977; 137(5): 588–93.Falko J.M., Guy J.T., Smith R.E. et al. Primary hyperparathyroidism and anemia. Arch Intern Med. 1976; 136(8): 887–9.Falko J.M., Guy J.T., Smith R.E. et al. Primary hyperparathyroidism and anemia. Arch Intern Med. 1976; 136(8): 887–9.Bhadada S.K., Sridhar S., Ahluwalia J. et al. Anemia and thrombocytopenia improves after curative parathyroidectomy in a patient of primary hyperparathyroidism (PHPT). J Clin Endocrinol Metab. 2012; 97(5): 1420–2. DOI: 10.1210/jc.2011-2845.Bhadada S.K., Sridhar S., Ahluwalia J. et al. Anemia and thrombocytopenia improves after curative parathyroidectomy in a patient of primary hyperparathyroidism (PHPT). J Clin Endocrinol Metab. 2012; 97(5): 1420–2. DOI: 10.1210/jc.2011-2845.De Keukeleire S., Muylle K., Tsoumalis G. et al. Primary hyperparathyroidism associated to thrombocytopenia: an issue to consider? Clin Cases Miner Bone Metab. 2017; 14: 97–100. DOI: 10.11138/ccmbm/2017.14.1.097.De Keukeleire S., Muylle K., Tsoumalis G. et al. Primary hyperparathyroidism associated to thrombocytopenia: an issue to consider? Clin Cases Miner Bone Metab. 2017; 14: 97–100. DOI: 10.11138/ccmbm/2017.14.1.097.Tanaka M., Komaba H., Fukagawa M. Emerging association between parathyroid hormone and anemia in hemodialysis patients. Ther Apher Dial. 2018; 22(3): 242–5. DOI: 10.1111/1744-9987.12685.Tanaka M., Komaba H., Fukagawa M. Emerging association between parathyroid hormone and anemia in hemodialysis patients. Ther Apher Dial. 2018; 22(3): 242–5. DOI: 10.1111/1744-9987.12685.Sonkar S.K., Singh H.P., Sonkar G.K. et al. Association of Vitamin D and secondary hyperparathyroidism with anemia in diabetic kidney disease. J Fam Med Prim care. 2018; 7(4): 815–8. DOI: 10.4103/jfmpc.jfmpc_174_17.Sonkar S.K., Singh H.P., Sonkar G.K. et al. Association of Vitamin D and secondary hyperparathyroidism with anemia in diabetic kidney disease. J Fam Med Prim care. 2018; 7(4): 815–8. DOI: 10.4103/jfmpc.jfmpc_174_17.Sethi S.K., Bansal S.B., Wadhwani N. et al. Myelofibrosis-induced erythropoietin-resistant anemia due to severe refractory hyperparathyroidism. Kidney Int Rep. 2018; 3: 1010–4. DOI: 10.1016/j.ekir.2018.04.003.Sethi S.K., Bansal S.B., Wadhwani N. et al. Myelofibrosis-induced erythropoietin-resistant anemia due to severe refractory hyperparathyroidism. Kidney Int Rep. 2018; 3: 1010–4. DOI: 10.1016/j.ekir.2018.04.003.Свинарева Д.А. Роль паратиреоидного гормона (ПТГ(1-34)) в регуляции гомеостаза костной и кроветворной тканей. Терапевтический архив. 2009; 81(1): 87–91.Svinareva D.A. The role of parathyroid hormone in regulation of homeostasis of bone and hemopoietic tissues. Terapevticheskiy arkhiv. 2009, 81(1): 87–91 (In Russian).Kumbasar B., Taylan I., Kazancioglu R. et al. Myelofibrosis secondary to hyperparathyroidism. Exp Clin Endocrinol Diabetes. 2004; 112(3): 127–30. DOI: 10.1055/s-2004-817820.Kumbasar B., Taylan I., Kazancioglu R. et al. Myelofibrosis secondary to hyperparathyroidism. Exp Clin Endocrinol Diabetes. 2004; 112(3): 127–30. DOI: 10.1055/s-2004-817820.Huang S.-C., Wu V.-C., Chou G. et al. Benign parathyroid adenoma presenting with unusual parathyroid crisis, anemia and myelofibrosis. J Formos Med Assoc. 2007; 106(2 Suppl): S13–6. DOI: 10.1016/s0929-6646(09)60346-6.Huang S.-C., Wu V.-C., Chou G. et al. Benign parathyroid adenoma presenting with unusual parathyroid crisis, anemia and myelofibrosis. J Formos Med Assoc. 2007; 106(2 Suppl): S13–6. DOI: 10.1016/s0929-6646(09)60346-6.Greenfield E.M., Gornik S.A., Horowitz M.C. et al. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res. 1993; 8(10): 1163–71. DOI: 10.1002/jbmr.5650081003.Greenfield E.M., Gornik S.A., Horowitz M.C. et al. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res. 1993; 8(10): 1163–71. DOI: 10.1002/jbmr.5650081003.Liu J.Y., Brass D.M., Hoyle G.W. et al. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol. 1998; 153(6): 1839–47. DOI: 10.1016/s0002-9440(10)65698-2.Liu J.Y., Brass D.M., Hoyle G.W. et al. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol. 1998; 153(6): 1839–47. DOI: 10.1016/s0002-9440(10)65698-2.Baradaran A., Nasri H. Intensification of anemia by secondary hyperparathyroidism in hemodialysis patients. Med J Islam World Acad Sci. 2001; 14(4): 161–6.Baradaran A., Nasri H. Intensification of anemia by secondary hyperparathyroidism in hemodialysis patients. Med J Islam World Acad Sci. 2001; 14(4): 161–6.Bhadada S.K., Bhansali A., Ahluwalia J. et al. Anaemia and marrow fibrosis in patients with primary hyperparathyroidism before and after curative parathyroidectomy. Clin Endocrinol. 2009; 70(4): 527–32. DOI: 10.1111/j.13652265.2008.03346.x.Bhadada S.K., Bhansali A., Ahluwalia J. et al. Anaemia and marrow fibrosis in patients with primary hyperparathyroidism before and after curative parathyroidectomy. Clin Endocrinol. 2009; 70(4): 527–32. DOI: 10.1111/j.13652265.2008.03346.x.Meytes D., Bogin E., Ma A. Effect of parathyroid hormone on erythropoiesis. J Clin Invest. 1981; 67(5): 1263–9. DOI: 10.1172/jci110154.Meytes D., Bogin E., Ma A. Effect of parathyroid hormone on erythropoiesis. J Clin Invest. 1981; 67(5): 1263–9. DOI: 10.1172/jci110154.Sikole A. Pathogenesis of anaemia in hyperparathyroidism. Med Hypotheses. 2000; 54(2): 236–8. DOI: 10.1054/mehy.1999.0027.Sikole A. Pathogenesis of anaemia in hyperparathyroidism. Med Hypotheses. 2000; 54(2): 236–8. DOI: 10.1054/mehy.1999.0027.Koury M.J., Bondurant M.C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990; 248(4953): 378–81. DOI: 10.1126/science.2326648.Koury M.J., Bondurant M.C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990; 248(4953): 378–81. DOI: 10.1126/science.2326648.Caro J., Brown S., Miller O. et al. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med. 1979; 93(3): 449–58.Caro J., Brown S., Miller O. et al. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med. 1979; 93(3): 449–58.Rao D.S., Shih M.S., Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993; 328(3): 171–5. DOI: 10.1056/NEJM199301213280304.Rao D.S., Shih M.S., Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993; 328(3): 171–5. DOI: 10.1056/NEJM199301213280304.Petrova N.V., Svinareva D.A., Nifontova I.N., et al. Stromal regulation of hemopoietic stem cells in long-term human bone marrow tissue cultures under the effect of parathyroid hormone. Bull Exp Biol Med. 2006;2(4):527–30. DOI: 10.1007/s10517-006-0408-5Petrova N.V., Svinareva D.A., Nifontova I.N., et al. Stromal regulation of hemopoietic stem cells in long-term human bone marrow tissue cultures under the effect of parathyroid hormone. Bull Exp Biol Med. 2006;2(4):527–30. DOI: 10.1007/s10517-006-0408-5Svinareva D.A., Nifontova I.N., Chertkov I.L., Drize N.I. Changed homing of hemopoietic precursor cells after long-term treatment with parathyroid hormone. Bulletin of experimental biology and medicine. 2006; 142(1): 86–9. DOI: 10.1007/s10517-006-0299-5.Svinareva D.A., Nifontova I.N., Chertkov I.L., Drize N.I. Changed homing of hemopoietic precursor cells after long-term treatment with parathyroid hormone. Bulletin of experimental biology and medicine. 2006; 142(1): 86–9. DOI: 10.1007/s10517-006-0299-5.Calvi L.M., Bromberg O., Rhee Y. et al. Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood. 2012; 119(11): 2489–99. DOI: 10.1182/blood-2011-06-360933.Calvi L.M., Bromberg O., Rhee Y. et al. Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood. 2012; 119(11): 2489–99. DOI: 10.1182/blood-2011-06-360933.Foldes J., Wilson P., Saeed S.M. et al. Parathyroid stimulation after bleeding in man. Acta Endocrinol. 1992; 127(2): 138–41. DOI: 10.1530/acta.0.1270138.Foldes J., Wilson P., Saeed S.M. et al. Parathyroid stimulation after bleeding in man. Acta Endocrinol. 1992; 127(2): 138–41. DOI: 10.1530/acta.0.1270138.Perris A.D., MacManus J.P., Whitfield J.F. et al. Parathyroid glands and mitotic stimulation in rat bone marrow after hemorrhage. Am J Physiol. 1971; 220(3): 773–8. DOI: 10.1152/ajplegacy.1971.220.3.773.Perris A.D., MacManus J.P., Whitfield J.F. et al. Parathyroid glands and mitotic stimulation in rat bone marrow after hemorrhage. Am J Physiol. 1971; 220(3): 773–8. DOI: 10.1152/ajplegacy.1971.220.3.773.Panda S., Mishra A., Jena M. et al. Study of red cell fragility in different stages of chronic kidney disease in relation to parathyroid hormone. J Clin Diagn Res. 2017; 11(8): BC29–32. DOI: 10.7860/JCDR/2017/27344.10514.Panda S., Mishra A., Jena M. et al. Study of red cell fragility in different stages of chronic kidney disease in relation to parathyroid hormone. J Clin Diagn Res. 2017; 11(8): BC29–32. DOI: 10.7860/JCDR/2017/27344.10514.Smith E.M., Tangpricha V. Vitamin D and anemia: insights into an emerging association. Curr Opin Endocrinol Diabetes Obes. 2015; 22(6): 432–8. DOI: 10.1097/MED.0000000000000199.Smith E.M., Tangpricha V. Vitamin D and anemia: insights into an emerging association. Curr Opin Endocrinol Diabetes Obes. 2015; 22(6): 432–8. DOI: 10.1097/MED.0000000000000199.Zughaier S.M., Alvarez J.A., Sloan J.H. et al. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J Clin Transl Endocrinol. 2014; 1(1): 19–25. DOI: 10.1016/j.jcte.2014.01.003.Zughaier S.M., Alvarez J.A., Sloan J.H. et al. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J Clin Transl Endocrinol. 2014; 1(1): 19–25. DOI: 10.1016/j.jcte.2014.01.003.Bacchetta J., Zaritsky J.J., Sea J.L. et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014; 25(3): 564–72. DOI: 10.1681/ASN.2013040355.Bacchetta J., Zaritsky J.J., Sea J.L. et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014; 25(3): 564–72. DOI: 10.1681/ASN.2013040355.Walker M.D., Cong E., Lee J.A. et al. Vitamin D in primary hyperparathyroidism: Effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab. 2015; 100(9): 3443–51. DOI: 10.1210/jc.2015-2022.Walker M.D., Cong E., Lee J.A. et al. Vitamin D in primary hyperparathyroidism: Effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab. 2015; 100(9): 3443–51. DOI: 10.1210/jc.2015-2022.Рукавицин О.А. Анемия хронических заболеваний: отдельные аспекты патогенеза и пути коррекции. Онкогематология. 2016; 11(1): 37–46. DOI: 10.17650/1818-8346-2016-11-1-37-46.Rukavitsyn O.A. Anemia of chronic diseases: the important aspects of pathogenesis and treatment. Oncohematologiya. 2016; 11(1): 37–46. DOI: 10.17650/1818-8346-2016-11-1-37-46. (In Russian).Khan A.A., Hanley D.A., Rizzoli R. et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017; 28(1): 1–19. DOI: 10.1007/s00198-016-3716-2.Khan A.A., Hanley D.A., Rizzoli R. et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017; 28(1): 1–19. DOI: 10.1007/s00198-016-3716-2.Wilhelm S.M., Wang T.S., Ruan D.T. et al. The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016; 151(10): 959–68. DOI: 10.1001/jamasurg.2016.2310.Wilhelm S.M., Wang T.S., Ruan D.T. et al. The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016; 151(10): 959–68. DOI: 10.1001/jamasurg.2016.2310.Hyperparathyroidism (primary): diagnosis, assessment and initial management. London, 2019. Available at: https://www.nice.org.uk/guidance/ng132/resources/hyperparathyroidism-primary-diagnosis-assessment-and-initial-management-pdf-66141715991749.Hyperparathyroidism (primary): diagnosis, assessment and initial management. London, 2019. Available at: https://www.nice.org.uk/guidance/ng132/resources/hyperparathyroidism-primary-diagnosis-assessment-and-initial-management-pdf-66141715991749.Herndon J.G., Helmick C.G., Sattin R.W. Chronic medical conditions and risk of fall injury events at home in older adults. J Am Geriatr Soc. 1997; 45(6): 739–43. DOI: 10.1111/j.1532-5415.1997.tb01480.x.Herndon J.G., Helmick C.G., Sattin R.W. Chronic medical conditions and risk of fall injury events at home in older adults. J Am Geriatr Soc. 1997; 45(6): 739–43. DOI: 10.1111/j.1532-5415.1997.tb01480.x.Katz I.R., Beaston-Wimmer P., Parmelee P. et al. Failure to thrive in the elderly: exploration of the concept and delineation of psychiatric components. J Geriatr Psychiatry Neurol. 1993; 6(3): 161–9. DOI: 10.1177/089198879300600305.Katz I.R., Beaston-Wimmer P., Parmelee P. et al. Failure to thrive in the elderly: exploration of the concept and delineation of psychiatric components. J Geriatr Psychiatry Neurol. 1993; 6(3): 161–9. DOI: 10.1177/089198879300600305.

The authors declare that there are no conflicts of interest present.